Another dengue live attenuated tetravalent vaccine (DLAV) was developed very recently and it showed a rapid increase of IFNg+TNF-α+-producing CD4+ T cells and then CD8+ T cells within 8–14 days after vaccination. This evidence concerns the gene IFNG and dengue disease.